ArticleBritish journal of cancer2006
A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer.
Article in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.Journal of translational medicine · 2012Trial
- A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.Clinical breast cancer · 2008Trial
- The carcinogenic capacity of arsenic in normal epithelial breast cells and double-positive breast cancer cells.Medicine and pharmacy reports · 2024Article
- Additional prognostic value of polymorphisms within the 3'-untranslated region of programmed cell death pathway genes in early-stage breast cancer.Frontiers in immunology · 2024Article
- The prognostic value of stem cell markers in triple-negative breast cancer.Pathology oncology research : POR · 2023Article
- Article
- Evaluation of the Expression of HER2 and c-KIT Proteins as Prognostic Markers in Superficial Bladder Urothelial Carcinoma.Research and reports in urology · 2021Article
- C-Kit receptor and tryptase expressing mast cells correlate with angiogenesis in breast cancer patients.Oncotarget · 2018Article
- Alterations of oncogenes expression in NK cells in patients with cancer.Immunity, inflammation and disease · 2017Article
- Intratumoral CD3+ T-lymphocytes immunoexpression and its association with c-Kit, angiogenesis, and overall survival in malignant canine mammary tumors.Analytical cellular pathology (Amsterdam) · 2015Article
- c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules.Journal of translational medicine · 2012Article
- Expression of c-kit protein in cancer vs. normal breast tissue.Contemporary oncology (Poznan, Poland) · 2012Article
- c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis.Pathology oncology research : POR · 2010Article
- Columnar cell lesions and pseudoangiomatous hyperplasia like stroma: is there an epithelial-stromal interaction?International journal of clinical and experimental pathology · 2009Article
- Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome.British journal of cancer · 2009Article
- Article
- Identification of Novel Biomarkers Associated With the Prognosis and Potential Pathogenesis of Breast Cancer via Integrated Bioinformatics Analysis.Technology in cancer research & treatmentArticle
- A Potential Tumor Suppressor Gene Named miR-508-5p Inhibited the Proliferation and Invasion of Human Melanoma Cells by Targeting KIT.Technology in cancer research & treatmentArticle
- Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.In vivo (Athens, Greece)Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the c-kit expression in breast cancer, 217 invasive ductal carcinomas of the breast were immunohistochemically stained for c-kit protein. The c-kit expression was positive in 59 (27%) of 217 tumours, while the c-kit expression was negative in 158 (73%) of 217 tumours. There was a significant correlation between a negative expression of the c-kit protein and lymph node metastasis (P < 0.0001), and the incidence of a negative expression of the c-kit protein increased as the number of the metastatic lymph nodes increased (P = 0.0003). The c-kit expression did not significantly correlate with the tumour size, nuclear grade, oestrogen receptor status, MIB-1 counts and p53 protein expression. A univariate analysis indicated the patients with the negative c-kit expression to have a worse disease-free survival (DFS) than those with the positive c-kit expression (P = 0.0041), while a multivariate analysis determined lymph node metastases and the MIB-1 counts to be independently significant factors for DFS. In conclusion, a loss of the c-kit expression was found in about three-fourth of invasive ductal carcinoma of the breast and was associated with lymph node metastases. The prognostic implications of the c-kit expression seem to be due to fact that a loss of the c-kit expression is associated with an advanced stage of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.